BCCIP在卵巢恶性肿瘤的表达及临床意义分析

The expression of BCCIP in malignant ovarian tiusses and its significances

目的:初步研究卵巢恶性肿瘤组织中BCCIP蛋白(BRCA2和CDKN1A相互作用蛋白)的表达水平及其相关临床资料。方法:采用免疫组化染色方法检测BCCIP蛋白在38例正常卵巢组织、52例卵巢恶性肿瘤组织(其中卵巢上皮恶性肿瘤26例、生殖细胞肿瘤11例、性索间质肿瘤15例),采用单因素多元方差分析BCCIP蛋白表达水平与卵巢恶性肿瘤患者临床病例特点的相关性。结果:免疫组化结果显示BCCIP蛋白在51.9%(27/52)的卵巢恶性肿瘤组织中(其中Ⅰ期10例、Ⅱ期25例、Ⅲ期12例、Ⅳ期5例)表达量显著下降(P<0.05),且根据FIGO 2000分期ⅡB～Ⅳ期卵巢恶性肿瘤组织有66.7%(18/27)显著下降(P<0.05)。结论:在卵巢恶性肿瘤组织中BCCIP蛋白表达水平显著下降。其蛋白表达水平对判断卵巢恶性肿瘤的患者的预后有一定的价值。

Objective：To investigate the expression of BCCIP protein in ovarian malignant tissues and the relation of its clinic.Methods：To detect the expression level of BCCIP protein in 38 caces of normal ovarian tissues and 52 cases of malignant ovarian（26 cases of epithial malignant,11 cases of germ cell tumor,15 cases of sex cord tumor）by immunohistochemistry（IHC）.Univariate analyses was used to make clear the relationship of BCCIP protein expression and clinic data of patients.Results：The result of IHC manifest that significantly reduced BCCIP protein expression in 51.9% of 52 cases（27/52）,especially（P0.05）,according to TIGO 2000 stage ⅡB-stage Ⅳ ovarian malignant tumor tissue reduced BCCIP protein expression in 66.7% of 27 cases（18/27）（P0.05）.Conclusion：In malignant ovarian tissues,protein of BCCIP reduced significantly.The expression of BCCIP protein could be a prognosis factor for malignan ovarian tumor patients.